JP2020537672A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537672A5
JP2020537672A5 JP2020521991A JP2020521991A JP2020537672A5 JP 2020537672 A5 JP2020537672 A5 JP 2020537672A5 JP 2020521991 A JP2020521991 A JP 2020521991A JP 2020521991 A JP2020521991 A JP 2020521991A JP 2020537672 A5 JP2020537672 A5 JP 2020537672A5
Authority
JP
Japan
Prior art keywords
independently selected
alkyl
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020521991A
Other languages
English (en)
Japanese (ja)
Other versions
JP7292271B2 (ja
JP2020537672A (ja
Filing date
Publication date
Priority claimed from GBGB1717260.2A external-priority patent/GB201717260D0/en
Application filed filed Critical
Publication of JP2020537672A publication Critical patent/JP2020537672A/ja
Publication of JP2020537672A5 publication Critical patent/JP2020537672A5/ja
Priority to JP2023093474A priority Critical patent/JP7654031B2/ja
Application granted granted Critical
Publication of JP7292271B2 publication Critical patent/JP7292271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020521991A 2017-10-20 2018-10-11 炎症性障害の治療のための新規化合物及びその医薬組成物 Active JP7292271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093474A JP7654031B2 (ja) 2017-10-20 2023-06-06 炎症性障害の治療のための新規化合物及びその医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
GB1717260.2 2017-10-20
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093474A Division JP7654031B2 (ja) 2017-10-20 2023-06-06 炎症性障害の治療のための新規化合物及びその医薬組成物

Publications (3)

Publication Number Publication Date
JP2020537672A JP2020537672A (ja) 2020-12-24
JP2020537672A5 true JP2020537672A5 (cg-RX-API-DMAC7.html) 2021-11-11
JP7292271B2 JP7292271B2 (ja) 2023-06-16

Family

ID=60481889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521991A Active JP7292271B2 (ja) 2017-10-20 2018-10-11 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2023093474A Active JP7654031B2 (ja) 2017-10-20 2023-06-06 炎症性障害の治療のための新規化合物及びその医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023093474A Active JP7654031B2 (ja) 2017-10-20 2023-06-06 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (30)

Country Link
US (3) US11564923B2 (cg-RX-API-DMAC7.html)
EP (2) EP4265254A3 (cg-RX-API-DMAC7.html)
JP (2) JP7292271B2 (cg-RX-API-DMAC7.html)
KR (1) KR102757425B1 (cg-RX-API-DMAC7.html)
CN (2) CN117534670A (cg-RX-API-DMAC7.html)
AR (1) AR113784A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018350592B2 (cg-RX-API-DMAC7.html)
CA (1) CA3079449A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020005200A2 (cg-RX-API-DMAC7.html)
DK (1) DK3697784T5 (cg-RX-API-DMAC7.html)
ES (1) ES2967432T3 (cg-RX-API-DMAC7.html)
FI (1) FI3697784T5 (cg-RX-API-DMAC7.html)
GB (1) GB201717260D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063998T2 (cg-RX-API-DMAC7.html)
IL (2) IL273943B2 (cg-RX-API-DMAC7.html)
LT (1) LT3697784T (cg-RX-API-DMAC7.html)
MA (1) MA50391B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003863A (cg-RX-API-DMAC7.html)
MY (1) MY205443A (cg-RX-API-DMAC7.html)
PH (1) PH12020550230A1 (cg-RX-API-DMAC7.html)
PL (1) PL3697784T3 (cg-RX-API-DMAC7.html)
PT (1) PT3697784T (cg-RX-API-DMAC7.html)
RS (1) RS64800B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003516TA (cg-RX-API-DMAC7.html)
SI (1) SI3697784T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300377T1 (cg-RX-API-DMAC7.html)
TW (2) TWI805629B (cg-RX-API-DMAC7.html)
WO (1) WO2019076716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002166B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ, インコーポレイテッド イオンチャネルモジュレーター
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
MX2024000517A (es) 2021-07-12 2024-01-31 Galapagos Nv Tratamiento de enfermedades inflamatorias.
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP7882100B2 (ja) * 2022-12-07 2026-06-30 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
EP4652166A1 (en) 2023-01-18 2025-11-26 Galapagos N.V. Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders
CN120584114A (zh) 2023-01-19 2025-09-02 加拉帕戈斯股份有限公司 用于治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病和增生性疾病的咪唑并[4,5-b]吡啶衍生物
WO2026098666A1 (zh) * 2024-11-11 2026-05-15 杭州领业医药科技有限公司 一种tyk2抑制剂的共晶及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) * 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2014531449A5 (cg-RX-API-DMAC7.html)
JP2010523522A5 (cg-RX-API-DMAC7.html)
CA2817317C (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2018528244A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2007507494A5 (cg-RX-API-DMAC7.html)
JP2018115191A5 (cg-RX-API-DMAC7.html)
CN101969951B (zh) 化合物在制备治疗关节炎的药物中的方法
JP2012518634A5 (cg-RX-API-DMAC7.html)
JP2017520613A5 (cg-RX-API-DMAC7.html)
JP2016525102A5 (cg-RX-API-DMAC7.html)
JP2014528433A5 (cg-RX-API-DMAC7.html)
JP2017511365A5 (cg-RX-API-DMAC7.html)
JP2020526549A5 (cg-RX-API-DMAC7.html)
PH12015500294B1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP2013502431A5 (cg-RX-API-DMAC7.html)
FI3697784T3 (fi) Imidatso[4,5-b]pyridiiniyhdisteet ja niiden farmaseuttiset koostu- mukset tulehduksellisten häiriöiden hoitoa varten
JP2019536768A5 (cg-RX-API-DMAC7.html)
JP2023523241A5 (cg-RX-API-DMAC7.html)
JP2020532547A5 (cg-RX-API-DMAC7.html)
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
JP2014114295A5 (cg-RX-API-DMAC7.html)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2019516739A5 (cg-RX-API-DMAC7.html)
RU2013136778A (ru) Ингибиторы гистондезацетилазы, композиции и способы их применения